Hemorrhage

Endocrinology·MeSH: Hemorrhage

Prevalence

10.1 / 100K

Incidence

128.7 / 100K/yr

14 drugs in development·10 companies·6 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
Jada	Organon & Co. (OGN)
tranexamic acid	NEXUS BIOPHARMA INC (NEXS)

Phase 3(4)

Drug	Company
Apixaban	Cidara Therapeutics, Inc. (CDTX)
gtx-104	Grace Therapeutics, Inc. (GRCE)
Oxytocin	Valneva SE (VALN)
Statins	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Phase 1(1)

Drug	Company
Andexanet alfa	ASTRAZENECA PLC (AZN)

Unknown(3)

N/A(2)

Drug	Company
Carbetocin	ENANTA PHARMACEUTICALS INC (ENTA)
Oxytocin	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 4(2)

Drug	Company
Antibiotic	Crinetics Pharmaceuticals, Inc. (CRNX)
edoxaban	GH Research PLC (GHRS)

BioSniper tracks 14 drugs in development for Hemorrhage across 10 companies.

There are 6 clinical trials targeting Hemorrhage tracked by BioSniper.

The estimated prevalence of Hemorrhage is approximately 10.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.